Common Carcinomas by Body Part/Organ
Skin
Basal cell carcinoma (BCC) is the most common cancer in the United States and Europe, followed by squamous cell carcinoma (SCC), then malignant melanoma 1, 2, 3. BCC accounts for the vast majority of skin cancers, with SCC being at least 2 times less common 2. These predominantly affect sun-exposed areas, particularly the head and neck region 1.
- BCC: Most common overall cancer; slow-growing, locally invasive; rarely metastasizes
- SCC: Second most common skin cancer
- Melanoma: Third most common but most deadly skin cancer
Lung
Adenocarcinoma and squamous cell carcinoma are the predominant non-small cell lung carcinomas, with small cell carcinoma representing a distinct aggressive subtype 4. Lung cancers are historically divided into:
- Non-small cell carcinomas (majority):
- Adenocarcinoma (most common subtype)
- Squamous cell carcinoma
- Large cell carcinoma
- Small cell carcinoma: Aggressive, distinct treatment approach
Breast
Invasive ductal carcinoma of no special type is the most common breast cancer, accounting for approximately 75% of cases 5. Special histological types comprise up to 25% and include:
- Invasive ductal carcinoma (no special type): 75%
- Invasive lobular carcinoma: Consistently shows CDH1 gene inactivation
- Special types: Secretory, adenoid cystic, mucinous, tubular (each with distinct molecular profiles)
Ovary/Fallopian Tube/Peritoneum
High-grade serous carcinoma accounts for approximately 70% of ovarian carcinomas and 90% of advanced-stage (III/IV) cases 6, 7. The distribution is:
- High-grade serous carcinoma: 70% overall; associated with TP53 mutations; many actually originate from distal fallopian tube epithelium
- Clear cell carcinoma: Second most common
- Endometrioid carcinoma: Often low-stage, arising from endometriosis
- Mucinous carcinoma: Uncommon, usually stage I and unilateral
- Low-grade serous carcinoma: Rare; associated with BRAF/KRAS mutations
Colorectum
Adenocarcinoma is the predominant histologic type of colorectal cancer 8, 9. The immunohistochemical profile typically shows:
- Adenocarcinoma: CK7-negative, CK20-positive, CDX2-positive pattern
- Associated with familial syndromes (FAP, Lynch syndrome) in hereditary cases
Bladder/Urothelial Tract
Urothelial (transitional cell) carcinoma constitutes more than 90% of bladder cancers 10. The breakdown is:
- Urothelial carcinoma: >90%
- Squamous cell carcinoma: 3%
- Adenocarcinoma: 2%
- Small cell carcinoma: 1%
Prostate
Adenocarcinoma is essentially the only primary carcinoma type in the prostate 9, 11. Diagnosis relies on:
- Adenocarcinoma: Nearly 100% of prostate cancers
- Identified by PSA elevation and characteristic immunohistochemistry
Thyroid
Papillary thyroid carcinoma is the most common thyroid malignancy, representing a well-differentiated indolent tumor 12. The spectrum includes:
- Papillary carcinoma: Most common; well-differentiated
- Follicular carcinoma: Well-differentiated
- Medullary carcinoma: Frequently metastasizes
- Anaplastic carcinoma: Poorly differentiated, fulminant, worst prognosis
Liver
Hepatocellular carcinoma is the primary liver malignancy 9. Immunohistochemical markers include:
- Hepatocellular carcinoma: CK7-negative, CK20-negative, Hep Par-1 positive
Cervix/Vulva/Vagina/Anus/Penis
Squamous cell carcinoma is the predominant carcinoma type in these HPV-associated sites 13. These are strongly associated with human papillomavirus infection.
Pancreas
Adenocarcinoma is the primary pancreatic carcinoma 9. Immunohistochemical profile shows:
- Adenocarcinoma: CK7-positive, CK20-variable pattern
Kidney
Renal cell carcinoma is the characteristic kidney malignancy 9, 11. Immunohistochemical profile:
- Renal cell carcinoma: CK7-negative, CK20-negative pattern
Key Clinical Pitfalls
When evaluating carcinomas, always consider metastatic disease versus primary tumors—immunohistochemistry panels using CK7/CK20 patterns with additional markers (TTF-1, ER, PR, PSA, etc.) are essential for determining tissue of origin 9.
For cancers of unknown primary (CUP), systematic immunohistochemical workup is mandatory to identify the likely primary site and guide treatment, as approximately 15-20% of CUP patients have favorable subtypes that benefit from site-specific therapy 9, 11.